EACR congress 2023

Illuminate PD1/PD-L1 Interactions: Explore immune checkpoint activation in situ 

We are thrilled to introduce our new product Naveni™ PD1/PD-L1 Atto647N
Unlocking the potential of immune checkpoint inhibition therapy calls for precise patient stratification. While PD-L1 is a commonly used biomarker, its correlation with immunotherapy outcomes isn’t always linear. Addressing this challenge, Navinci presents Naveni™ PD1/PD-L1 Atto647N, the pioneering fluorescent assay for in situ detection of PD1/PD-L1 interactions. 

Poster presentations

– Multiplexed proximity ligation-based method uncovers immune checkpoint activation in the context of the tumor microenvironment  

Number EACR23-0207, session Immunotherapy, Wednesday, 14 June 2023 between 10:15 – 18:15 ,
Ka I  Au Ieong 

Download poster

Navinci Technology

Learn how to maximize information from every analysis by localizing and quantifying proteins, their interactions, and modifications in situ at a molecular level. In situ methods are commonly used in the cancer research field, and studies of protein-protein interactions (PPI) and protein translational modifications (PTM) are essential for:

• Deep biological knowledge
• Biomarker discovery
• Patient stratification
• Drug testing
• Treatment validation

 

All our products are based on our proprietary Naveni Proximity Ligation technology with dual antibody recognition giving you more specific and sensitive detection of your target of interest. Click here to read about the technology.

To our flexible products – to use with your primary antibodies

To our target specific products – primary antibody system included, for the precise detection of PD1/PD-L1 interaction and phosphorylated proteins. 

Navinci team at EACR

Ida Hansson (Area Manager Europe), Hampus Elofsson (Senior scientist), Ka I Au Ieong (Production Manager),  and Daniel Ekman (Distributor Support Manager).  

We would love to meet you, please book a meeting with us here